Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Cancel Anytime
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99per week for the first 24weeks
Just $1.99per week for the first 24weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

This file photo shows Patheon’s analytical development lab. Patheon is the target of a $1.4-billion (U.S.) friendly takeover.

Canada is losing another of its mid-cap public health-care companies, with the move to privatize Toronto-based contract drug maker Patheon Inc.

The company's majority shareholder, New York hedge fund JLL Partners, is partnering with giant Dutch health care company Royal DSM to buy out Patheon's minority shareholders for $9.32 (U.S.) per share, or about $9.72 (Canadian). Patheon will then be combined with Royal DSM's own contract drug making unit to create a company with about $2-billion in annual sales.

The announcement of the offer – which has been approved by a special committee of Patheon's board – drove the company's shares up more than 60 per cent on the Toronto Stock Exchange Tuesday. The stock had been trading at around $6 before the offer was made.

Story continues below advertisement

This is the latest in a series of go-private transactions that have diminished the ranks of mid to large cap Canadian health care stocks.

Two weeks ago specialty drug distributor Paladin Labs Inc. agreed to sell itself to Pennsylvania-based Endo Health Solutions Inc. in a deal valued at about $2-billion. And in October medical lab testing company CML HealthCare Inc. was absorbed by rival LifeLabs Medical Laboratory Services in a $1.2-billion deal.

Alan Ridgeway, an analyst at Paradigm Capital Inc. in Toronto, said the Canadian market now "has only a handful of true mid cap biotech companies," although he noted that some smaller companies are growing and moving into that space.

Under the complex Patheon takeover deal, JLL and Royal DSM will set up a new holding company that has yet to be named. JLL will hold 51 per cent and Royal DSM – a European manufacturing giant that makes everything from biomedical devices to food supplements to thermoplastics – will hold 49 per cent.

Patheon's business, which develops and manufactures drugs for other pharmaceutical companies, will be folded in with Royal DSM's similar business, called DSM Pharmaceutical Products. The new company will have 8,300 employees, and 23 offices in North America, Europe Latin America and Australia.

The two companies are "highly complementary, Royal DSM's chief financial officer Rolf-Dieter Schwalb told analysts on a conference call. "After a successful completion of the transaction [the new company] will have an unmatched end-to-end offering from drug products to active substances," he said.

Patheon's chief executive officer Jim Mullen will become CEO of the new entity. He said on a conference call that the company's customers "have indicated a strong desire to streamline their outsourcing network" so it made sense to combine Patheon with another firm. Customers "want to work with fewer companies with broader capabilities and capacity," he said.

Story continues below advertisement

Because DSM is in a similar business, it "is a very logical strategic partner," Mr. Mullen said.

This is not the first time JLL has tried to take Patheon private. In 2009 it tried to buy the company for $2 per share, but Patheon's management and board resisted and there was a prolonged proxy fight. Still, JLL built up its a majority stake during that process.

The current deal for Patheon is set to close in the first half of 2014, but it still needs a variety if regulatory, legal and shareholder approvals.

Report an error Editorial code of conduct
Tickers mentioned in this story
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

UPDATED: Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies